Hemostasis and the Coagulation Cascade

Core Idea

Hemostasis prevents bleeding through a coordinated sequence of vascular constriction, platelet adhesion and aggregation into a plug, and activation of the coagulation cascade—extrinsic and intrinsic pathways converging on a common pathway that generates thrombin and cross-linked fibrin clot. Anticoagulants and fibrinolysis then limit clot extent and promote dissolution.

Explainer

From blood composition, you know that blood contains platelets (cell fragments from megakaryocytes) and plasma proteins including clotting factors. From enzyme kinetics, you understand that enzymes catalyze reactions and that cascades can amplify a small initial signal into a massive downstream response. Hemostasis — the process of stopping bleeding — is a masterclass in biological signal amplification, where a tiny injury to a vessel wall triggers a precisely ordered chain of events that seals the breach within minutes.

Hemostasis proceeds in three overlapping phases. Primary hemostasis begins within seconds of vascular injury. The damaged vessel constricts reflexively, reducing blood flow to the area. Exposed collagen and von Willebrand factor (vWF) in the subendothelial matrix attract circulating platelets, which adhere via surface glycoprotein receptors (GPIb binds vWF, GPVI binds collagen). Activated platelets change shape from smooth discs to spiny spheres, degranulate to release ADP and thromboxane A2, and recruit more platelets that aggregate together via fibrinogen bridges between GPIIb/IIIa receptors. The result is a fragile platelet plug — sufficient for small injuries but not strong enough to seal significant damage on its own.

Secondary hemostasis reinforces the platelet plug with a meshwork of cross-linked fibrin, generated by the coagulation cascade. This cascade is a series of serine proteases, each activating the next in sequence, producing exponential amplification. Two pathways initiate it: the extrinsic pathway begins when tissue factor (TF), exposed on damaged cells, binds factor VII and activates factor X — this is the fast-start mechanism triggered by actual tissue injury. The intrinsic pathway begins when factor XII contacts exposed collagen or negatively charged surfaces, triggering a slower chain through factors XI and IX. Both pathways converge on the common pathway at factor X, which combines with factor V to form prothrombinase. Prothrombinase converts prothrombin (factor II) into thrombin, the central enzyme of coagulation. Thrombin then cleaves fibrinogen into fibrin monomers that polymerize into strands, and factor XIII cross-links these strands into a stable, insoluble mesh that reinforces the platelet plug.

The system would be dangerous without brakes. Anticoagulant mechanisms confine clotting to the injury site: antithrombin III inactivates thrombin and factor Xa, protein C (activated by thrombomodulin on intact endothelium) degrades factors Va and VIIIa, and tissue factor pathway inhibitor (TFPI) shuts down the extrinsic trigger. Once healing begins, fibrinolysis dissolves the clot: plasminogen, trapped within the fibrin mesh, is converted to plasmin by tissue plasminogen activator (tPA), and plasmin systematically degrades the fibrin network. The balance between clotting and anticoagulation is precise — tipping toward excessive clotting produces thrombosis (stroke, pulmonary embolism), while tipping toward insufficient clotting produces hemorrhage. Most anticoagulant drugs (heparin, warfarin, direct oral anticoagulants) and thrombolytic therapies (tPA) target specific steps in this cascade.